Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 7/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1190642 | 1.00 | OXTR (0.51) | OXTRAVPR1AMEN1KMT2AMAPK1 | |
| SCHEMBL1190859 | 1.00 | OXTR (0.51) | OXTRAVPR1AMEN1KMT2AMAPK1 | |
| SCHEMBL82476 | 0.86 | KMT2A (0.51) | MEN1KMT2AMAPTGAAL3MBTL1 | |
| SCHEMBL16373718 | 0.85 | GAA (0.59) | MEN1KMT2AMAPTGAAL3MBTL1 | |
| SCHEMBL3094416 | 0.85 | GAA (0.45) | MEN1KMT2AMAPTGAAL3MBTL1 | |
| SCHEMBL3190543 | 0.85 | GAA (0.45) | MEN1KMT2AMAPTGAAL3MBTL1 | |
| SCHEMBL3094410 | 0.85 | GAA (0.45) | MEN1KMT2AMAPTGAAL3MBTL1 | |
| SCHEMBL28473802 | 0.84 | OXTR (0.50) | OXTRAVPR1AMEN1KMT2AMAPK1 | |
| SCHEMBL28476929 | 0.84 | OXTR (0.50) | OXTRAVPR1AMEN1KMT2AMAPK1 | |
| SCHEMBL28473805 | 0.84 | OXTR (0.50) | OXTRAVPR1AMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| EP-1345910-B9 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-8586608-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-RE43431-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-05-29 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110046168-A1 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-01-14 | — | — | US | disclosed |
| EP-2112140-A1 | Chinazolin derivatives, medicine containing these compounds, application thereof and method for their production | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-10-28 | — | — | EP | disclosed |
| EP-1345910-B1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-7019012-B2 | Tyrosine inhibitors; antitumor agents; respiratory system disorders | BOEHRINGER INGELHEIM INTERNATIONAL PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | OXTR 2867/4885AVPR1A 2164/4885MEN1 2032/4885 |
| US-20060100223-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, RET, ABL1 | OXTR 3266/4885AVPR1A 2658/4885MEN1 2225/4885 |
| US-20100010023-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, TYK2 | OXTR 3355/4885AVPR1A 2703/4885MEN1 1853/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | OXTR 2231/4885AVPR1A 482/4885MEN1 13/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | OXTR 2556/4885AVPR1A 396/4885MEN1 63/4885 |
| US-20110046168-A1 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CNKSR1, ABL1, JAK1 | OXTR 3186/4885AVPR1A 2584/4885MEN1 1512/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | OXTR 2556/4885AVPR1A 396/4885MEN1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.